ArticleNature communications2026
An end-to-end generalizable deep learning framework to comprehensively analyze transcriptional regulation.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- WormSORT: A detection-based multiple object tracking model for individual silkworms in breeding environments.PLoS computational biology · 2026Article
- An end-to-end generalizable deep learning framework to comprehensively analyze transcriptional regulation.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Genome annotation currently requires performing dozens of molecular assays in hundreds of cell and tissue samples, an expensive endeavor which is impractical to replicate across all species and conditions of interest. Here, we introduce BioSeq2Seq, a deep learning framework that infers cell-line-specific molecular assays widely used for genome annotation by leveraging a tri-modal input: evolutionarily conserved DNA sequence features, together with cell-line-specific transcriptional activity and directionality captured by a single run-on sequencing assay. BioSeq2Seq enables flexible genome annotation tasks through parameterized configurations of input features and output targets, combined with gradient-guided architectural refinement for specific biological objectives. Our model demonstrates high accuracy across four downstream tasks, showing improvements of 14.27% in histone modification prediction, 2.50% in functional element identification, and 2.90% in gene expression prediction compared to state-of-the-art methods. In transcription factor binding site (TFBS) prediction, it maintains performance comparable to that of leading existing approaches. By achieving competitive performance across tasks with single-cell-line input data, BioSeq2Seq provides an efficient and low-cost alternative for genome annotation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.